

Chapter 24

REFERENCES

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry*. 1994;51:8-19.
2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)*. 4th ed. Washington, DC: American Psychiatric Association; 1994.
3. Nestler EJ. Molecular basis of neural plasticity underlying addiction. *Nat Rev Neurosci*. 2001;2:119-128.
4. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness. Implications for treatment, insurance, and outcomes evaluation. *JAMA*. 2000;284:1689-1695.
5. Gardner EL. Brain-reward mechanisms. In: Lowinson JH, Ruiz P, Millman RB, Langrod JG, eds. *Substance Abuse. A Comprehensive Textbook*. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkins; 2005:48-97.
6. Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. *JAMA*. 2001;285:2355-2362.
7. Moore RD, Bone LR, Geller G, Mamon JA, Stokes EJ, Levine DM. Prevalence, detection, and treatment of alcoholism in hospitalized patients. *JAMA*. 1989;261:403-407.
8. Kitchens JM. Does this patient have an alcohol problem? *JAMA*. 1994;272:1782-1787.
9. Schorling JB, Buchsbaum D. Screening for alcohol and drug abuse. *Med Clin North Am*. 1997;81:845-865.
10. Chiang PP. Perioperative management of the alcohol-dependent patient. *Am Fam Physician*. 1995;52:2267-2273.
11. Perry SW. Irrational attitudes toward addicts and narcotics. *Bull N Y Acad Med*. 1985;61:706-727.
12. Bander KW, Goldman DS, Schwartz MA, Rabinowitz E, English JT. Survey of attitudes among three specialists in a teaching hospital toward alcoholics. *J Med Educ*. 1987;62:17-24.
13. May JA, Warltier DC, Pagel PS. Attitudes of anesthesiologists about addiction and its treatment: a survey of Illinois and Wisconsin members of the American Society of Anesthesiologists. *J Clin Anesth*. 2002;14:284-289.
14. Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. *JAMA*. 2003;289:2370-2378.
15. Compton P, Charuvastra VC, Kintaudi K, Ling W. Pain responses in methadone-maintained opioid abusers. *J Pain Symptom Manage*. 2000;20:237-245.
16. Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. *J Gen Intern Med*. 2002;17:327-333.
17. Breitbart W, Rosenfeld BD, Passik SD, McDonald MV, Thaler H, Portenoy RK. The undertreatment of pain in ambulatory AIDS patients. *Pain*. 1996;65:243-249.
18. Gilson AM, Joranson DE. U.S. policies relevant to the prescribing of opioid analgesics for the treatment of pain in patients with addictive disease. *Clin J Pain*. 2000;18:S91-S98.
19. Cherubin CE, Sapira JD. The medical complications of drug addiction and the medical assessment of the intravenous drug user: 25 years later. *Ann Intern Med*. 1993;119:1017-1028.
20. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Eldin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. *Clin Infect Dis*. 2000;30:579-581.
21. Passaro DJ, Werner SB, McGee J, MacKenzie WR, Vugia DJ. Wound botulism associated with black tar heroin among injecting drug users. *JAMA*. 1998;279:859-863.
22. Takahashi TA, Merrill JO, Boyko EJ, Bradley KA. Type and location of injection drug use-related soft tissue infections predict hospitalization. *J Urban Health*. 2003;80:127-136.
23. Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. *Circulation*. 1998;98:2936-2948.
24. Von Reyn CF, Levy BS, Arbeit RD, Friedland G, Crumpacker CS. Infective endocarditis: an analysis based on strict case definitions. *Ann Intern Med*. 1981;94:505-518.
25. Frontera JA, Gradon JD. Right-side endocarditis in injection drug users: review of proposed mechanisms of pathogenesis. *Clin Infect Dis*. 2000;30:374-379.
26. Hecht SR, Berger M. Right-sided endocarditis in intravenous drug users. Prognostic features in 102 episodes. *Ann Intern Med*. 1992;117:560-566.
27. Li JS, Sexton DJ, Mick N. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. *Clin Infect Dis*. 2000;30:633-638.
28. Boschini A, Smacchia C, Di Fine M, et al. Community-acquired pneumonia in a cohort of former injection drug users with or without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. *Clin Infect Dis*. 1996;23:107-113.

29. Scheidegger C, Zimmerli W. Incidence and spectrum of severe medical complications among hospitalized HIV-seronegative and HIV-seropositive narcotic drug users. *AIDS*. 1996;10:1407-1414.
30. Havlir DV, Barnes PF. Tuberculosis in patients with human immunodeficiency virus infection. *N Engl J Med*. 1999;340:367-373.
31. Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. *MMWR Recomm Rep*. 2000;49:1-51.
32. Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampin-induced methadone withdrawal. *N Engl J Med*. 1976;294:1104-1106.
33. Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. *N Engl J Med*. 1998;338:286-290.
34. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. *N Engl J Med*. 1999;341:556-562.
35. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. *JAMA*. 2000;284:450-456.
36. Backmund M, Meyer K, Von Zielonka M, Eichenlaub D. Treatment of hepatitis C infection in injection drug users. *Hepatology*. 2001;34:188-193.
37. Centers for Disease Control and Prevention (CDC). *HIV/AIDS Surveillance Report*. Atlanta, GA: CDC; 2000;12:1-41.
38. Centers for Disease Control and Prevention (CDC). Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. *MMWR Recomm Rep*. 1998;47:43-82.
39. Holmberg SD. The estimated prevalence and incidence of HIV in 96 large U.S. metropolitan areas. *Am J Public Health*. 1996;86:642-654.
40. Gourevitch MN, Friedland GH. Interactions between methadone and medications used to treat HIV infection: a review. *Mt Sinai J Med*. 2000;67:429-436.
41. Spies C, Tonnesen H, Andreasson S, Helander A, Conigrave K. Perioperative morbidity and mortality in chronic alcoholic patients. *Alcohol Clin Exp Res*. 2001;25:164S-170S.
42. Tonnesen H, Rosenberg J, Nielsen HJ, et al. Effect of preoperative abstinence on poor postoperative outcome in alcohol misusers: randomised controlled trial. *BMJ*. 1999;318:1311-1316.
43. Randin D, Vollenweider P, Tappy L, Jequier E, Nicod P, Scherrer U. Suppression of alcohol-induced hypertension by dexamethasone. *N Engl J Med*. 1995;332:1733-1777.
44. Clark LT, Friedman HS. Hypertension associated with alcohol withdrawal: assessment of mechanisms and complications. *Alcohol Clin Exp Res*. 1985;9:125-130.
45. Serdula MK, Koong SL, Williamson DF, et al. Alcohol intake and subsequent mortality: findings from NHANES I follow-up study. *J Stud Alcohol*. 1995;56:233-239.
46. Pagel PS, Kersten JR, Warltier DC. Mechanisms of myocardial protection produced by chronic ethanol consumption. *Pathophysiology*. 2004;10:121-129.
47. Brigden W, Robinson J. Alcoholic heart disease. *Br Med J*. 1964;2:1283-1289.
48. Friedman HS, Cirillo N, Schiano F, et al. Vasodilatory state of decompensated cirrhosis: relation to hepatic dysfunction, ascites and vasoactive substances. *Alcohol Clin Exp Res*. 1995;19:123-129.
49. Campillo B, Chabrier PE, Pelle G, et al. Inhibition of nitric oxide synthase in the forearm arterial bed of patients with advanced cirrhosis. *Hepatology*. 1995;22:1423-1429.
50. Lithell H, Aberg H, Selinus I, Hedstrand H. Alcohol intemperance and sudden death. *Br Med J (Clin Res Ed)*. 1987;294:1456-1458.
51. Heinemann HO. Alcohol and the lung. A brief review. *Am J Med*. 1977;63:81-85.
52. Fallon MB, Abrams GA. Pulmonary dysfunction in chronic liver disease. *Hepatology*. 2000;32:859-865.
53. Sacco RL, Elkind M, Boden-Albala B, et al. The protective effect of moderate alcohol consumption on ischemic stroke. *JAMA*. 1999;281:53-60.
54. Dufour MC. Chronic liver disease and cirrhosis. In: Everhart JE, ed. *Digestive Diseases in the United States: Epidemiology and Impact*. Washington, DC: National Institutes of Health; 1994:615-646.
55. Patel T. Surgery in the patient with liver disease. *Mayo Clin Proc*. 1999;74:593-599.
56. Garrison RN, Cryer HM, Howard DA, Polk Jr HC. Clarification of risk factors for abdominal operations in patients with hepatic cirrhosis. *Ann Surg*. 1984;199:648-655.
57. Gines P, Arroyo V. Hepatorenal syndrome. *J Am Soc Nephrol*. 1999;10:1833-1839.
58. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In: Hardman JG, Limbird LE, Gilman AG, eds. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. 10th ed. New York, NY: McGraw-Hill; 2001:399-427.
59. Office of National Drug Control Policy. *National Drug Control Strategy*. Washington, DC: ONDCP, Executive Office of the President, The White House; 2000.
60. Schultz JE, Hsu AK, Gross GJ. Morphine mimics the cardioprotective effect of ischemic preconditioning via a glibenclamide-sensitive mechanism in the rat heart. *Circ Res*. 1996;78:1100-1104.
61. Sporer KA. Acute heroin overdose. *Ann Intern Med*. 1999;130:584-590.
62. Smith WS, Matthay MA. Evidence for a hydrostatic mechanism in human neurogenic pulmonary edema. *Chest*. 1997;111:1326-1333.
63. Yin D, Mufson RA, Wang R, Shi Y. Fas-mediated cell death promoted by opioids. *Nature*. 1999;397:218.
64. Hershey LA. Meperidine and central neurotoxicity. *Ann Intern Med*. 1983;98:548-549.
65. Friedman EA, Tao TK. Disappearance of uremia due to heroin-associated nephropathy. *Am J Kidney Dis*. 1995;25:689-693.
66. US Department of Health and Human Services. *NIDA Research Report Series. Cocaine Abuse and Addiction*. Rockville, MD: National Institutes of Health; 1999. NIH publication 99-4342.
67. Kloner RA, Hale SH, Alker K, Rezkalla S. The effects of acute and chronic cocaine use on the heart. *Circulation*. 1992;85:407-419.
68. Lange RA, Hillis LD. Cardiovascular complications of cocaine use. *N Engl J Med*. 2001;345:351-358.
69. Mittleman MA, Mintzer D, Maclure M, Tofker GH, Sherwood JB, Muller JE. Triggering of myocardial infarction by cocaine. *Circulation*. 1999;99:2737-2741.
70. Qureshi AI, Suri MF, Guterman LR, Hopkins LN. Cocaine use and the likelihood of nonfatal myocardial infarction and stroke: data from the Third National Health and Nutrition Examination Survey. *Circulation*. 2001;103:502-506.

71. Egashira K, Morgan KG, Morgan JP. Effects of cocaine on excitation-contraction coupling of aortic smooth muscle from the ferret. *J Clin Invest*. 1991;87:1322-1328.
72. Dressler FA, Malekzadeh S, Roberts W. Quantitative analysis of amounts of coronary arterial narrowing in cocaine addicts. *Am J Cardiol*. 1990;65:303-308.
73. Albertson TE, Walby WF, Derlet RW. Stimulant-induced pulmonary toxicity. *Chest*. 1995;108:1140-1149.
74. Kissner DG, Lawrence WD, Selis JE, Flint A. Crack lung: pulmonary disease caused by cocaine abuse. *Am Rev Respir Dis*. 1987;136:1250-1252.
75. Kaufman MJ, Levin JM, Ross MH, et al. Cocaine-induced vasoconstriction detected in humans with magnetic resonance angiography. *JAMA*. 1998;279:376-380.
76. McCarron MM, Wood JD. The cocaine "body packer" syndrome: diagnosis and treatment. *JAMA*. 1983;250:1417-1420.
77. Nzerue CM, Hewan-Lowe K, Riley LJ Jr. Cocaine and the kidney: a synthesis of pathophysiologic and clinical perspectives. *Am J Kidney Dis*. 2000;35:783-795.
78. Volcy J, Nzerue CM, Oderinde A, Hewan-Iowe K. Cocaine-induced acute renal failure, hemolysis, and thrombocytopenia mimicking thrombotic thrombocytopenic purpura. *Am J Kidney Dis*. 2000;35:E3-E7.
79. Milroy CM, Clark JC, Forrest AR. Pathology of deaths associated with "Ecstasy" and "Eve" misuse. *J Clin Pathol*. 1996;49:149-153.
80. Fishman AP. Aminorex to fen/phen: an epidemic foretold. *Circulation*. 1999;99:156-161.
81. Brust JC. Vasculitis owing to substance abuse. *Neurol Clin*. 1997;15:945-957.
82. Brauer RB, Heidecke CD, Nathrath W, et al. Liver transplantation for the treatment of fulminant hepatic failure induced by the ingestion of ecstasy. *Transpl Int*. 1997;10:229-233.
83. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE. Triggering of myocardial infarction by marijuana. *Circulation*. 2001;103:2805-2809.
84. Wu TC, Tashkin DP, Djahed B, Rose JE. Pulmonary hazards of smoking marijuana as compared with tobacco. *N Engl J Med*. 1988;318:347-351.
85. Armen R, Kanel G, Reynolds T. Phencyclidine-induced malignant hyperthermia causing submassive liver necrosis. *Am J Med*. 1984;77:167-172.
86. Linden CH. Volatile substances of abuse. *Emerg Med Clin North Am*. 1990;8:559-578.
87. Jensen NH, Dragsted L, Christensen JK, Jorgensen JC, Qvist J. Severity of illness and outcome of treatment in alcoholic patients in the intensive care unit. *Intensive Care Med*. 1988;15:19-22.
88. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine working Group on Pharmacologic Management of Alcohol Withdrawal. *JAMA*. 1997;278:144-151.
89. Alldredge BK, Lowenstein DH. Status epilepticus related to alcohol abuse. *Epilepsia*. 1993;34:1033-1037.
90. Mitra S, Sinatra RS. Perioperative management of acute pain in the opioid-dependent patient. *Anesthesiology*. 2004;101:212-227.
91. Coffey SF, Dansky BS, Carrigan MH, Brady KT. Acute and protracted cocaine abstinence in an outpatient population: a prospective study of mood, sleep, and withdrawal symptoms. *Drug Alcohol Depend*. 2000;59:277-286.
92. Vaillant GE. Natural history of addiction and pathways to recovery. In: Graham AW, Schultz TK, Mayo-Smith MF, Ries RK, Wilford BB, eds. *Principles of Addiction Medicine*. 3rd ed. Chevy Chase, MD: American Society of Addiction Medicine; 2003:3-16.
93. Goodwin DW. Inpatient treatment of alcoholism—new life for the Minneapolis Plan. *N Engl J Med*. 1991;325:804-806.
94. O'Malley SS, Jaffe AJ, Chang G, et al. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. *Arch Gen Psychiatry*. 1996;53:217-224.
95. Littleton J. Acamprosate in alcohol dependence: how does it work? *Addiction*. 1995;90:1179-1188.
96. Mueller TI, Stout RL, Rudden S, et al. A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. *Alcohol Clin Exp Res*. 1997;21:86-92.
97. Kranzler HR, Bursleson JA, Korner P, et al. Placebo-controlled trial of fluoxetine as an adjunct to relapse prevention in alcoholics. *Am J Psychiatry*. 1995;152:391-397.
98. Wesson DR, Ling W, Smith DE. Prescription of opioids for treatment of pain in patients with addictive disease. *J Pain Symptom Manage*. 1993;8:289-296.
99. Piazza PV, Le Moal M. The role of stress in drug self-administration. *Trends Pharmacol Sci*. 1998;19:67-74.